Kernel density analysis of variable and conserved regions of the envelope proteins of human immunodeficiency virus type 1 and associated epitopes

AIDS Research and Human Retroviruses

Volumn 12, Issue 2, 1996, Pages 91-97

  Lauder, Ian J ^a   Lin, Hsiang Ju ^b   Siwak, Edward B ^b   Hollinger, F Blaine ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; B LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; STATISTICAL ANALYSIS;

EID: 0030031567     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.91     Document Type: Article

References (43)

1. Modrow S, Hahn BH, Shaw GM, Gallo RC, Wong-Staal F, and Wolf H: Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved and variable regions. J Virol 1987;61:570-578.
2. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, and Gregory TJ: Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp 120) expressed in Chinese hamster ovary cells. J Biol Chem 1990; 265:10373-10382.
3. Wang WK, Essex M, and Lee TH: Uncommon gp120 cysteine residues found in primary HIV-1 isolates. AIDS Res Hum Retroviruses 1995;11:185-188.
4. Moore JP, Sattentau QJ, Wyatt R, and Sodroski J: Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol 1994;68: 469-484.
5. Myers G, Korber B, Wain-Hobson S, Smith RF, and Pavlakis GN: Human retroviruses and AIDS 1993: A compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Biophysics. Los Alamos Laboratory, Los Alamos, 1993.
6. Lauder IJ: Direct kernel assessment of diagnostic probabilities. Biometrika 1983;70:251-256.
7. Lauder IJ, Lin HJ, Lau JYN, Siu TS, and Lai CL: The variability of the hepatitis B virus genome: statistical analysis and biological implications. Mol Biol Evol 1993;10:457-470.
8. Lin HJ, Lau JYN, Lauder IJ, Shi N, Lai CL, and Hollinger FB: The hepatitis C virus genome: A guide to its conserved sequences and candidate epitopes. Virus Res 1993;30:27-41.
9. Korber BTM, MacInnes K, Smith RF, and Myers G: Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 1994;68:6730-6744.
10. Yokoyama S, Chung L, and Gojobori T: Molecular evolution of the human immunodeficiency and related viruses. Mol Biol Evol 1988;5:237-251.
11. Li WH, Tanimura M, and Sharp PM: Rates and dates of divergence between AIDS virus nucleotide sequences. Mol Biol Evol 1988; 5:313-330.
12. Kaplan EB, and Elston RC: A subroutine package for maximum likelihood estimation (MAXlik). Inst Stat Mimeo Ser 823, 1972. Institute of Statistics, University of North Carolina, Chapel Hill.
13. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Holley LH, Karplus M, Bolognesi DP, Matthews TJ, Emini EA, and Putney SD: Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249: 932-935.
14. Ghiara JB, Stura EA, Stanfield RL, Profy AT, and Wilson IA: Crystal structure of the principal neutralization site of HIV-1. Science 1994;264:82-85.
15. Sullivan N, Thali M, Furman C, Ho DD, and Sodroski J: Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol 1993;67:3674-3679.
16. Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon SW, Fung MS, Traincard F, Pinkus M, Robey G, Robinson JE, Ho DD, and Sodroski J: Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J Virol 1993;67:6136-6151.
17. Broliden PA, von Gegerfelt A, Clapham P, Rosen J, Fenyo EM, Wahren B, and Broliden K: Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 1992;89:461-465.
18. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Rüker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67: 6642-6647.
19. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, Palese P, and Katinger H: Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994;68:4031-4034.
20. Johnson RP, Hammond SA, Trocha A, Siliciano RF, and Walker BD: Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J Virol 1994;68:3145-3153.
21. Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, Fischinger PJ, Gallo RC, DeLisi C, and Berzofsky JA: Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 1987;84:4249-4253.
22. Berzofsky JA, Bensussan A, Cease KB, Bourge JF, Cheynier R, Lurhuma Z, Salaun JJ, Gallo RC, Shearer GM, and Zagury D: Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature (London) 1988;334:706-708.
23. Pozzi G, Oggioni MR, Manganelli R, Medaglini D, Fischetti VA, Fenoglio D, Valle MT, Kunkl A, and Manca F: Human T-helper cell recognition of an immunodominant epitope of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. Vaccine 1994;12:1071-1077.
24. Johnson RP, Trocha A, Buchanan TM, and Walker BD: Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol 1993;67:438-445.
25. Hammond SA, Obah E, Stanhope P, Monell CR, Strand M, Robbins FM, Bias WB, Karr RW, Koenig S, and Siliciano RF: Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. J Immunol 1991;146:1470-1477.
26. Bell SJD, Cooper DA, Kemp BE, Doherty RR, and Penny R: Definition of an immunodominant T cell epitope contained in the envelope gp41 sequence of HIV-1. Clin Exp Immunol 1992; 87:37-45.
27. Johnson RP, Trocha A, Buchanan TM, and Walker BD: Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: Definition of minimum epitopes and analysis of the effects of sequence variation. J Exp Med 1992;175:961-971.
28. Safrit JT, Andrews CA, Zhu T, Ho DD, and Koup RA: Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: Recognition of autologous virus sequences within a conserved immunodominant epitope. J Exp Med 1994;179:463-472.
29. Gnann JW Jr, Nelson JA, and Oldstone MBA: Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol 1987;61:2639-2641.
30. Xu JY, Gorny MK, Palker T, Karwowska S, and Zolla-Pazner S: Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991;65: 4832-4838.
31. Isaguliants MG, Sukhanova LL, Levi M, Bobkov AP, Kalinina TI, Ruden U, Smirnov VD, and Wahren B: Linear epitopes of HIV-1, presented as hybrids with Escherichia coli β-galactosidase or synthetic peptides. AIDS Res Hum Retroviruses 1994;10:655-664.
32. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF III, Burton DR, and Ho DD: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.
33. Bukawa H, Fukushima J, Hamajima K, Kimura M, Tsuji T, Xin KQ, and Okuda K: Antibody responses raised against a conformational V3 loop peptide of HIV-1. Microbiol Immunol 1995;39:607-614.
34. Moore JP, Trkola A, Korber B, Boots LJ, Kessler JA H, McCutchan FE, Mascola J, Ho DD, Robinson J, and Conley AJ: A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol 1995;69:122-130.
35. Bour S, Geleziunas R, and Wainberg MA: The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev 1995;59:63-93.
36. Thali M, Furman C, Ho DD, Robinson J, Tilley S, Pinter A, and Sodroski J: Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 1992;66:5635-5641.
37. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, and Sodroski J: Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 1990;64:5701-5707.
38. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF III, and Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-4828.
39. Moore JP, McCutchan FE, Poon SW, Mascola J, Liu J, Cau Y, and Ho DD: Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994;68:8350-8364.
40. Gorney MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, and Zolla-Pazner S: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994;68:8312-8320.
41. Lin HJ, Siwak EB, Lauder JJ, and Hollinger FB: Single-strand conformation polymorphism study of human immunodeficiency virus type 1 RNA and DNA in plasma, peripheral blood mononuclear cells, and their virologie cultures. J Infect Dis 1995;171: 1619-1622.
42. Mutch D, Underwood J, Geysen M, and Rodda S: Comprehensive T-cell epitope mapping of HIV-1 env antigens reveals many areas recognized by HIV-1-seropositive and by low-risk HIV-1-seronegative individuals. J Acq Immune Defic Syndr 1994;7:879-890.
43. Littaua RA, Oldstone MBA, Takeda A, Debouck C, Wong JT, Tuazon CU, Moss B, Kievits F, and Ennis FA: An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag. J Virol 1991;65:4051-4056.